GenScript Biotech Corporation, a global provider of life science research and manufacturing services, has been awarded a Silver Medal by EcoVadis, a globally recognized business sustainability assessment platform. This achievement places GenScript in the top 15% of companies worldwide assessed for their sustainability practices. The company, which is a member of the United Nations Global Compact and a supplier partner of the Pharmaceutical Supply Chain Initiative, has made significant advancements in areas such as environment, labor and human rights, ethics, and sustainable procurement. GenScript's sustainability efforts are further supported by an "A" rating from MSCI ESG Ratings, a "Low Risk" rating from Morningstar Sustainalytics, and inclusion in the FTSE4Good Index Series. The company's carbon reduction targets have been approved by the Science Based Targets initiative, emphasizing its commitment to addressing climate change.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。